Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hsa_circ_0068871 regulates the miR-181a-5p/FGFR3 axis and activates STAT3 to promote BCa progression, and it may serve as a potential biomarker.
|
30999937 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Silencing or inhibition of mutant FGFR3 in bladder cancer cell lines is associated with decreased malignant potential, confirming its important driver role in UC.
|
30952872 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent precision medicine has shown that mutations in BC are frequently observed in FGFR3, RAS and PIK3CA genes, all of which correlate with RAS signaling networks.
|
31066120 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The FGFR3<sup>S249C</sup> mutation may therefore be used as a predictor of chemosensitivity in patients with BCa.
|
31316618 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PATIENT SUMMARY: We propose that APOBEC-mediated mutagenesis can generate clinically relevant driver mutations even within suboptimal motifs, such as in the case of FGFR3 S249C, one of the most common mutations in bladder cancer.
|
30975452 |
2019 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045).
|
30650148 |
2019 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this paper was to report the most pivotal trials that evaluated different families of targeted therapy in the treatment of BC, according to their biomarkers (FGFR3, EGFR, HER2, VEGF and PI3K/AKT/mTOR).
|
30977669 |
2019 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Regarding the association between mutated FGFR3 and bladder cancer, we found an OR 31 95% CI (15-64).
|
31028457 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer.
|
31377167 |
2019 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we show that HDAC6 loss or inhibition reduces FGFR3 accumulation in cells made tumorigenic by ectopic expression of a mutant activated version of FGFR3 together with the MYC oncoprotein and in a bladder cancer cell line whose tumorigenicity is dependent on expression of a translocated version of FGFR3.
|
29423038 |
2018 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings open up new possibilities for the treatment of bladder tumors displaying aberrant FGFR3 activation.
|
29463565 |
2018 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Human bladder cancer T24 and 5637 cell lines were transiently transfected with FGFR3-AS1-specific siRNA or negative control siRNA.
|
29226855 |
2018 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased levels of FGFR3 and PIK3CA mutated DNA in urine and plasma are indicative of later progression and metastasis in bladder cancer.
|
28069289 |
2017 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
|
28049011 |
2017 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further investigation showed that FGFR3 knockdown resulted in downregulation of DAPK1 in bladder cancer cell line, suggesting that FGFR3 may be an upstream factor of DAPK1.
|
28388658 |
2017 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The present study examined the utility of fibroblast growth factor receptor 3 (<i>FGFR3</i>) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC).
|
28927152 |
2017 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The GSE41035 dataset downloaded from Gene Expression Omnibus was used to identify the differentially expressed genes (DEGs) between bladder cancer cell line RT112 with or without depletion of FGFR3, and gene ontology enrichment analysis was performed.
|
28320388 |
2017 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer.
|
27091807 |
2016 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We assessed the performance of associating a FGFR3 mutation assay and a DNA methylation analysis to improve bladder cancer detection and to predict disease recurrence of NMIBC patients.
|
27586786 |
2016 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
FGFR3-TACC3 fusion transcripts were identified by RNA-FISH and RT-PCR in mouse xenograft FFPE tissues using the human BC cell lines RT112 and RT4.
|
27930669 |
2016 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our findings are consistent with the results of the TCGA data set for the "squamous-like" subtype of bladder cancer (n = 85), which revealed reduced overall expression of FGFR1 and FGFR2 in tumors compared to normal tissue, while expression of FGFR3 remained high.
|
27669755 |
2016 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In non-invasive BC, these mutations were related to high risk and grade (p<0.0001) as well as progression to muscle-invasive disease (p=0.01), whereas FGFR3 mutations were observed in low-grade BC (p=0.02) and patients with recurrences (p=0.05).
|
27611947 |
2016 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Analysing only previously reported point mutations, TERT mutations were found in 55% of patients with bladder cancer (independent of stage), FGFR3 mutations in 30% of patients with bladder cancer, PIK3CA in 14% and TP53 mutations in 12% of patients with bladder cancer.
|
26901314 |
2016 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 mutations are common in low-grade BC, while TP53 mutation or loss of RB1 is associated with muscle-invasive BC.
|
26924873 |
2016 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of endogenous FGFR3 impaired the activity of daidzein against bladder cancer, which suggested that the effect of daidzein was mainly mediated by FGFR3 pathway.
|
27268915 |
2016 |